How Gonadorelin Affects FSH

Gonadorelin (synthetic GnRH, gonadotropin-releasing hormone) acts at the level of the anterior pituitary gonadotrophs, binding GnRH receptors and stimulating the synthesis and pulsatile release of both LH and FSH. This is upstream of all other fertility-preserving pharmacological approaches: HCG acts at the level of the testis (bypassing the pituitary), and SERMs act at the pituitary but only by modifying feedback signals. Gonadorelin acts as the primary driver of the entire gonadotropin axis. Administered subcutaneously twice daily (to mimic physiological GnRH pulsatility), it maintains pituitary gonadotroph responsiveness and downstream testicular steroidogenesis and spermatogenesis. In patients with congenital hypogonadotropic hypogonadism (CHH), pulsatile GnRH therapy induced spermatogenesis in a median of 6 months, compared to 14 months for HCG plus HMG in a comparison by Zhang et al. (2019). In TRT patients, gonadorelin maintains pituitary function and prevents the testicular atrophy associated with HCG-only or SERM-only approaches.

FSH typically rises into the normal male range (1.5-12 IU/L) within 4-8 weeks of starting gonadorelin at standard doses (100-200 mcg subcutaneously twice daily). The response is less predictable than with SERMs because it depends on preserved pituitary GnRH receptor sensitivity, which can be reduced after prolonged suppression by exogenous androgens. LH rises simultaneously. Unlike HCG, the estradiol rise is more modest and proportionate, because gonadorelin stimulates physiological testosterone and FSH levels rather than the supraphysiological intratesticular testosterone that drives disproportionate aromatase activity with high-dose HCG.

Check LH, FSH, testosterone, and estradiol at baseline, then at 6-8 weeks after starting gonadorelin. For fertility protocols, semen analysis at 3 and 6 months is the primary outcome measure. If LH and FSH do not rise above 2 IU/L by 8 weeks, assess whether exogenous androgens are still suppressing the axis or whether gonadorelin dosing is insufficient. Timing of the blood draw relative to the most recent injection matters: draw at trough (12 hours after the previous dose) for the most reproducible baseline measurement.

The standard protocol for TRT fertility preservation using gonadorelin is 100 mcg subcutaneously twice daily. Twice-daily dosing is critical for maintaining pulsatility: continuous GnRH receptor stimulation (as would occur with a long-acting GnRH analogue) paradoxically downregulates the receptor and suppresses gonadotropin release. If the patient finds twice-daily injections impractical, HCG plus a SERM combination is a more patient-friendly alternative. The greatest limitation of gonadorelin in the TRT fertility context is the limited RCT evidence in this specific population: most gonadorelin spermatogenesis data comes from CHH patients (who have never suppressed their axis with AAS) rather than from TRT patients seeking recovery.